# Alessandro Bonifazi

List of Publications by Year
in descending order



| 54 | 1,278 | 304743 22 | 414414 32 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 54 | 54 | 54 | 1467 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Highly Selective Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R) Antagonists and Partial Agonists Based on Eticlopride and the D<sub>3</sub>R Crystal Structure: New Leads for Opioid Dependence Treatment. Journal of Medicinal Chemistry, 2016, 59, 7634-7650. | 6.4 | 73 |
| 2 | Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D<sub>2</sub>-Like Receptor Agonist. Molecular Pharmacology, 2016, 89, 457-466. | 2.3 | 62 |
| 3 | Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 10676-10691. | 6.4 | 58 |
| 4 | The highly selective dopamine D R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology, 2019, 158, 107597. | 4.1 | 51 |
| 5 | Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacology, 2018, 133, 264-275. | 4.1 | 50 |
| 6 | Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D<sub>3</sub> Receptor. Journal of Medicinal Chemistry, 2017, 60, 580-593. | 6.4 | 49 |
| 7 | 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts. Journal of Medicinal Chemistry, 2020, 63, 1779-1797. | 6.4 | 49 |
| 8 | Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R). Journal of Medicinal Chemistry, 2017, 60, 1478-1494. | 6.4 | 44 |
| 9 | Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D<sub>2</sub> Receptor (D<sub>2</sub>R) Biased Agonism. Journal of Medicinal Chemistry, 2017, 60, 2890-2907. | 6.4 | 43 |
| 10 | Novel and Potent Dopamine D<sub>2</sub> Receptor Go-Protein Biased Agonists. ACS Pharmacology and Translational Science, 2019, 2, 52-65. | 4.9 | 43 |
| 11 | Opioidâ€“galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744. | 8.2 | 41 |
| 12 | Favourable involvement of Î±2A-adrenoreceptor antagonism in the I2-imidazoline binding sites-mediated morphine analgesia enhancement. Bioorganic and Medicinal Chemistry, 2012, 20, 2259-2265. | 3.0 | 39 |
| 13 | New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. Annual Review of Pharmacology and Toxicology, 2021, 61, 609-628. | 9.4 | 36 |
| 14 | Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. BMC Cancer, 2014, 14, 921. | 2.6 | 35 |
| 15 | Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Agonist Selectivity. Journal of Medicinal Chemistry, 2016, 59, 2973-2988. | 6.4 | 33 |
| 16 | Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D<sub>3</sub> Receptor Antagonists and Partial Agonists. Journal of Medicinal Chemistry, 2019, 62, 9061-9077. | 6.4 | 30 |
| 17 | Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands. Bioorganic and Medicinal Chemistry, 2015, 23, 4000-4012. | 3.0 | 29 |
| 18 | The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D<sub>3</sub> Receptor (D<sub>3</sub>R) Selective Agonists. Journal of Medicinal Chemistry, 2019, 62, 6287-6314. | 6.4 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2Bâ€Selective NMDA Receptor Antagonists with a Benzo[7]annulenâ€7â€amine Scaffold. ChemMedChem, 2017, 12, 1212-1222. | 3.2 | 25 |
| 20 | Synthesis and Biological Evaluation of a Novel Series of Heterobivalent Muscarinic Ligands Based on Xanomeline and 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1). Journal of Medicinal Chemistry, 2014, 57, 9065-9077. | 6.4 | 24 |
| 21 | GluN2Bâ€Selective Nâ€Methylâ€<scp>dâ€</scp>aspartate (NMDA) Receptor Antagonists Derived from 3â€Benzazepines: Synthesis and Pharmacological Evaluation of Benzo[7]annulenâ€7â€amines. ChemMedChem, 2014, 9, 741-751. | 3.2 | 23 |
| 22 | 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D4 Receptor. Journal of Medicinal Chemistry, 2018, 61, 3712-3725. | 6.4 | 23 |
| 23 | Novel Potent N-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor Antagonists or Ïƒ<sub>1</sub> Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring. Journal of Medicinal Chemistry, 2015, 58, 8601-8615. | 6.4 | 22 |
| 24 | 1,4-Dioxane, a Suitable Scaffold for the Development of Novel M<sub>3</sub> Muscarinic Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 1783-1787. | 6.4 | 20 |
| 25 | Dopamine D<sub>4</sub> Receptor-Selective Compounds Reveal Structureâ€“Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry, 2019, 62, 3722-3740. | 6.4 | 20 |
| 26 | Structureâ€“Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability. Journal of Medicinal Chemistry, 2020, 63, 2343-2357. | 6.4 | 20 |
| 27 | Structureâ€“Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11. Reversed Enantioselectivity of 1,4-Dioxane Derivatives in Î±<sub>1</sub>-Adrenergic and 5-HT<sub>1A</sub> Receptor Binding Sites Recognition. Journal of Medicinal Chemistry, 2013, 56, 584-588. | 6.4 | 19 |
| 28 | Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines. Bioorganic and Medicinal Chemistry, 2014, 22, 6638-6646. | 3.0 | 19 |
| 29 | The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over Î±1-adrenoceptor andÂD2-like receptor subtypes. European Journal of Medicinal Chemistry, 2017, 125, 233-244. | 5.5 | 17 |
| 30 | Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters. ACS Pharmacology and Translational Science, 2021, 4, 503-516. | 4.9 | 17 |
| 31 | Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5748-5751. | 2.2 | 15 |
| 32 | Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1,4-dioxane fragments. European Journal of Medicinal Chemistry, 2017, 137, 327-337. | 5.5 | 14 |
| 33 | Novel Dual-Target Î¼-Opioid Receptor and Dopamine D<sub>3</sub> Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management. Journal of Medicinal Chemistry, 2021, 64, 7778-7808. | 6.4 | 14 |
| 34 | Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66. ACS Medicinal Chemistry Letters, 2014, 5, 647-651. | 2.8 | 13 |
| 35 | Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. European Journal of Medicinal Chemistry, 2019, 168, 461-473. | 5.5 | 13 |
| 36 | Multitarget 1,4-Dioxane Compounds Combining Favorable D<sub>2</sub>-like and 5-HT<sub>1A</sub> Receptor Interactions with Potential for the Treatment of Parkinsonâ€™s Disease or Schizophrenia. ACS Chemical Neuroscience, 2019, 10, 2222-2228. | 3.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D<sub>3</sub> Dopamine Receptor. ACS Chemical Neuroscience, 2020, 11, 3309-3320. | 3.5 | 13 |
| 38 | Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability. European Journal of Medicinal Chemistry, 2020, 208, 112674. | 5.5 | 13 |
| 39 | Novel Fluorescent Ligands Enable Single-Molecule Localization Microscopy of the Dopamine Transporter. ACS Chemical Neuroscience, 2020, 11, 3288-3300. | 3.5 | 12 |
| 40 | Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Bitopic Ligands. Journal of Medicinal Chemistry, 2021, 64, 15313-15333. | 6.4 | 12 |
| 41 | Novel Highly Potent and Selective Sigma1 Receptor Antagonists Effectively Block the Binge Eating Episode in Female Rats. ACS Chemical Neuroscience, 2020, 11, 3107-3116. | 3.5 | 11 |
| 42 | Preferential Gs protein coupling of the galanin Gal1 receptor in the Âμ-opioid-Gal1 receptor heterotetramer. Pharmacological Research, 2022, 182, 106322. | 7.1 | 11 |
| 43 | Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3255-3259. | 2.2 | 10 |
| 44 | Investigation of the Role of Chirality in the Interaction with Ïƒ Receptors and Effect on Binge Eating Episode of a Potent Ïƒ1 Antagonist Analogue of Spipethiane. ACS Chemical Neuroscience, 2019, 10, 3391-3397. | 3.5 | 10 |
| 45 | Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D3R Bitopic Agonists. ACS Medicinal Chemistry Letters, 2020, 11, 1956-1964. | 2.8 | 10 |
| 46 | Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. Biomolecules, 2021, 11, 570. | 4.0 | 10 |
| 47 | A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter. ACS Chemical Neuroscience, 2019, 10, 3946-3952. | 3.5 | 9 |
| 48 | A Novel Class of Dopamine D<sub>4</sub> Receptor Ligands Bearing an Imidazoline Nucleus. ChemMedChem, 2016, 11, 1819-1828. | 3.2 | 7 |
| 49 | Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells. ACS Medicinal Chemistry Letters, 2019, 10, 511-516. | 2.8 | 7 |
| 50 | Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus. Journal of Medicinal Chemistry, 2020, 63, 5763-5782. | 6.4 | 7 |
| 51 | Scaffold Hybridization Strategy Leads to the Discovery of Dopamine D3 Receptor-Selective or Multitarget Bitopic Ligands Potentially Useful for Central Nervous System Disorders. ACS Chemical Neuroscience, 2021, 12, 3638-3649. | 3.5 | 7 |
| 52 | Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D<sub>2</sub> or D<sub>3</sub> Receptor Agonists. Journal of Medicinal Chemistry, 2021, 64, 16088-16105. | 6.4 | 7 |
| 53 | Evidence for a Stereoselective Mechanism of Action for Nonâ€competitive Antagonism of the D3 Dopamine Receptor by Extendedâ€Length Bitopic Ligands. FASEB Journal, 2018, 32, 827.12. | 0.5 | 0 |
| 54 | Novel Dopamine D4 Receptorâ€Selective Compounds Reveal Structureâ€Activity Relationships that Engender Agonist Efficacy. FASEB Journal, 2019, 33, lb40. | 0.5 | 0 |